Lewsiville, TX, August 15, 2012
med fusion and Theranostics Health have entered into a Market Development Agreement to validate the clinical utility of Theranostics’ TheraLink™ Assays for use in patients with malignant diseases. The goal of this relationship is to help accelerate advancement of new methods in molecular diagnostics testing and their use in personalized predictive treatments.